Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CLARIVATE PLCCLVT · Entity 4778 | Director | May 13, 2026 | May 15, 2026 |
| Centessa Pharmaceuticals plcCNTA · Entity 35581 | Director · Chief Executive Officer | July 21, 2025 | July 21, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CLARIVATE PLC
Report date May 13, 2026 · Filed May 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 170,601 |
Ending reported balance
After 2026-05-14 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-13 · Tax withholding · Disposed 8,178 · Balance 108,337 F1: Represents shares withheld for taxes. Row 2 · 2026-05-14 · Grant · Acquired 62,264 · Balance 170,601 F2: Annual non-employee director award of restricted share units granted pursuant to the Clarivate Plc Amended and Restated 2019 Incentive Award Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld for taxes.
F2: Annual non-employee director award of restricted share units granted pursuant to the Clarivate Plc Amended and Restated 2019 Incentive Award Plan.
Centessa Pharmaceuticals plc
Report date July 21, 2025 · Filed July 21, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 221,017 |
Last balance in matching sequence
After 2025-07-21 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2025-07-21 · Exercise / conversion · Acquired 55,000 · Balance 276,017 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Row 2 · 2025-07-21 · Sale · Disposed 55,000 · Balance 221,017 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2024. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.80 to $16.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.85 · Expires 2033-02-01 | Direct | 150,000 |
Reported balance
After 2025-07-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-07-21 · Exercise / conversion · Disposed 55,000 · Balance 150,000 F5: 1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 1, 2023. F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy trust | 38,000 |
Reported balance
Holding disclosure · report date 2025-07-21 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 38,000 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F4: These shares are held directly in a trust, for which the Reporting Person and his spouse serve as trustees. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2024.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.80 to $16.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4: These shares are held directly in a trust, for which the Reporting Person and his spouse serve as trustees.
F5: 1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 1, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 14, 2026 Filed May 15, 2026 22:26 UTC | CLARIVATE PLC CLVT · Entity 4778 | GrantOrdinary Shares | 62,264 | $0.00 | $0.00 |
DisclosureSEC source: 0001764046-26-000069 · wk-form4_1778883990.xml · nonDerivative · entry 2 SAHA SAURABH · CIK 0001861926 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,601 F2 · shares: Annual non-employee director award of restricted share units granted pursuant to the Clarivate Plc Amended and Restated 2019 Incentive Award Plan. Read SEC document |
| May 13, 2026 Filed May 15, 2026 22:26 UTC | CLARIVATE PLC CLVT · Entity 4778 | Tax withholdingOrdinary Shares | 8,178 | $2.44 | $19,954.32 |
DisclosureSEC source: 0001764046-26-000069 · wk-form4_1778883990.xml · nonDerivative · entry 1 SAHA SAURABH · CIK 0001861926 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,337 F1 · shares: Represents shares withheld for taxes. Read SEC document |
| July 21, 2025 Filed Jul 21, 2025 23:39 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | Exercise / conversionShare Option (right to buy) · Derivative | 55,000 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001847903-25-000119 · wk-form4_1753141162.xml · derivative · entry 4 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 150,000 Underlying: Ordinary Shares · 55,000 shares Expires 2033-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 1, 2023. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| July 21, 2025 Filed Jul 21, 2025 23:39 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | SaleOrdinary Shares | 55,000 | $15.92 | $875,600.00 |
DisclosureSEC source: 0001847903-25-000119 · wk-form4_1753141162.xml · nonDerivative · entry 2 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 221,017 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.80 to $16.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 21, 2025 Filed Jul 21, 2025 23:39 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | Exercise / conversionOrdinary Shares | 55,000 | $3.85 | $211,750.00 |
DisclosureSEC source: 0001847903-25-000119 · wk-form4_1753141162.xml · nonDerivative · entry 1 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 276,017 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 20, 2025 Filed Jun 21, 2025 00:58 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | Exercise / conversionShare Option (right to buy) · Derivative | 55,000 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001847903-25-000095 · wk-form4_1750467532.xml · derivative · entry 4 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 205,000 Underlying: Ordinary Shares · 55,000 shares Expires 2033-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 1, 2023. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 20, 2025 Filed Jun 21, 2025 00:58 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | SaleOrdinary Shares | 55,000 | $12.63 | $694,826.00 |
DisclosureSEC source: 0001847903-25-000095 · wk-form4_1750467532.xml · nonDerivative · entry 2 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 221,017 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.50 to $12.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 20, 2025 Filed Jun 21, 2025 00:58 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | Exercise / conversionOrdinary Shares | 55,000 | $3.85 | $211,750.00 |
DisclosureSEC source: 0001847903-25-000095 · wk-form4_1750467532.xml · nonDerivative · entry 1 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 276,017 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| May 20, 2025 Filed May 20, 2025 21:44 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | Exercise / conversionShare Option (right to buy) · Derivative | 55,000 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001847903-25-000076 · wk-form4_1747777437.xml · derivative · entry 4 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 260,000 Underlying: Ordinary Shares · 55,000 shares Expires 2033-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 1, 2023. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| May 20, 2025 Filed May 20, 2025 21:44 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | SaleOrdinary Shares | 55,000 | $12.71 | $699,110.50 |
DisclosureSEC source: 0001847903-25-000076 · wk-form4_1747777437.xml · nonDerivative · entry 2 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 221,017 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.265 to $13.125, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 20, 2025 Filed May 20, 2025 21:44 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | Exercise / conversionOrdinary Shares | 55,000 | $3.85 | $211,750.00 |
DisclosureSEC source: 0001847903-25-000076 · wk-form4_1747777437.xml · nonDerivative · entry 1 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 276,017 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| May 07, 2025 Filed May 9, 2025 01:02 UTC | CLARIVATE PLC CLVT · Entity 4778 | GrantOrdinary Shares | 39,473 | $0.00 | $0.00 |
DisclosureSEC source: 0001764046-25-000075 · wk-form4_1746752548.xml · nonDerivative · entry 2 SAHA SAURABH · CIK 0001861926 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,515 F2 · shares: Annual non-employee director award of restricted share units granted pursuant to the Clarivate Plc 2019 Incentive Award Plan. Read SEC document |
| May 06, 2025 Filed May 9, 2025 01:02 UTC | CLARIVATE PLC CLVT · Entity 4778 | Tax withholdingOrdinary Shares | 4,974 | $4.17 | $20,741.58 |
DisclosureSEC source: 0001764046-25-000075 · wk-form4_1746752548.xml · nonDerivative · entry 1 SAHA SAURABH · CIK 0001861926 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,042 F1 · shares: Represents shares withheld for taxes. Read SEC document |
| April 22, 2025 Filed Apr 22, 2025 21:43 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | SaleOrdinary Shares | 40,344 | $12.43 | $501,475.92 |
DisclosureSEC source: 0001847903-25-000055 · wk-form4_1745358187.xml · nonDerivative · entry 2 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 221,017 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.23 to $12.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 21, 2025 Filed Apr 22, 2025 21:43 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | SaleOrdinary Shares | 14,656 | $12.29 | $180,100.26 |
DisclosureSEC source: 0001847903-25-000055 · wk-form4_1745358187.xml · nonDerivative · entry 1 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 261,361 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.23 to $12.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 20, 2025 Filed Mar 21, 2025 20:53 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | SaleOrdinary Shares | 55,000 | $16.69 | $918,060.00 |
DisclosureSEC source: 0001847903-25-000045 · wk-form4_1742590408.xml · nonDerivative · entry 1 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 276,017 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.35 to $17.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:17 UTC | CLARIVATE PLC CLVT · Entity 4778 | PurchaseOrdinary Shares | 58,275 | $4.36 | $254,079.00 |
DisclosureSEC source: 0001764046-25-000026 · wk-form4_1741209422.xml · nonDerivative · entry 1 SAHA SAURABH · CIK 0001861926 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,016 F1 · price: The price reported is a weighted average price. The prices actually paid ranged from $4.31 to $4.43, inclusive. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 20, 2025 Filed Feb 20, 2025 22:45 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | SaleOrdinary Shares | 775 | $16.54 | $12,820.52 |
DisclosureSEC source: 0001847903-25-000035 · wk-form4_1740091504.xml · nonDerivative · entry 2 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 331,017 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.54 to $16.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 20, 2025 Filed Feb 20, 2025 22:45 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | SaleOrdinary Shares | 54,225 | $15.92 | $863,267.42 |
DisclosureSEC source: 0001847903-25-000035 · wk-form4_1740091504.xml · nonDerivative · entry 1 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 331,792 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.52 to $16.505, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 21:56 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | GrantShare Option (right to buy) · Derivative | 900,000 | $0.00 Strike: $16.90 | $0.00 |
DisclosureSEC source: 0001847903-25-000027 · wk-form4_1738706184.xml · derivative · entry 3 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 900,000 Underlying: Ordinary Shares · 900,000 shares Expires 2035-02-03 F4 · derivative.exercise_date: 1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 3, 2025. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 21:56 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | Tax withholdingOrdinary Shares | 43,381 | $16.92 | $734,006.52 |
DisclosureSEC source: 0001847903-25-000027 · wk-form4_1738706184.xml · nonDerivative · entry 1 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 386,017 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · shares: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted share units. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:15 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | SaleOrdinary Shares | 1,625 | $16.19 | $26,314.76 |
DisclosureSEC source: 0001847903-25-000011 · wk-form4_1737580539.xml · nonDerivative · entry 2 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 429,398 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.16 to $16.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:15 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | SaleOrdinary Shares | 53,375 | $15.76 | $841,115.28 |
DisclosureSEC source: 0001847903-25-000011 · wk-form4_1737580539.xml · nonDerivative · entry 1 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 431,023 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.16 to $16.145, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 31, 2024 Filed Dec 31, 2024 21:31 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | Tax withholdingOrdinary Shares | 36,263 | $16.35 | $592,900.05 |
DisclosureSEC source: 0001847903-24-000199 · wk-form4_1735680675.xml · nonDerivative · entry 1 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 484,398 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · shares: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted share units. Read SEC document |
| December 20, 2024 Filed Dec 20, 2024 22:22 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | SaleOrdinary Shares | 55,000 | $17.44 | $959,057.00 |
DisclosureSEC source: 0001847903-24-000186 · wk-form4_1734733345.xml · nonDerivative · entry 1 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 520,661 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.12 to $17.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 06, 2024 Filed Dec 6, 2024 22:03 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | Exercise / conversionShare Option (right to buy) · Derivative | 87,496 | $0.00 Strike: $5.84 | $0.00 |
DisclosureSEC source: 0001847903-24-000178 · wk-form4_1733522614.xml · derivative · entry 4 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,869,485 Underlying: Ordinary Shares · 87,496 shares Expires 2031-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the shares subject to such option shall vest and become exercisable on February 19, 2022 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| December 06, 2024 Filed Dec 6, 2024 22:03 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | SaleOrdinary Shares | 87,496 | $18.46 | $1,615,254.91 |
DisclosureSEC source: 0001847903-24-000178 · wk-form4_1733522614.xml · nonDerivative · entry 2 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 575,661 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.23 to $18.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 06, 2024 Filed Dec 6, 2024 22:03 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | Exercise / conversionOrdinary Shares | 87,496 | $5.84 | $510,976.64 |
DisclosureSEC source: 0001847903-24-000178 · wk-form4_1733522614.xml · nonDerivative · entry 1 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 663,157 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 21:22 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | Exercise / conversionShare Option (right to buy) · Derivative | 299 | $0.00 Strike: $5.84 | $0.00 |
DisclosureSEC source: 0001847903-24-000175 · wk-form4_1732742538.xml · derivative · entry 4 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,956,981 Underlying: Ordinary Shares · 299 shares Expires 2031-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to such option shall vest and become exercisable on February 19, 2022 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 21:22 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | SaleOrdinary Shares | 299 | $18.23 | $5,450.77 |
DisclosureSEC source: 0001847903-24-000175 · wk-form4_1732742538.xml · nonDerivative · entry 2 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 575,661 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2024. Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 21:22 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | Exercise / conversionOrdinary Shares | 299 | $5.84 | $1,746.16 |
DisclosureSEC source: 0001847903-24-000175 · wk-form4_1732742538.xml · nonDerivative · entry 1 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 575,960 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| November 22, 2024 Filed Nov 22, 2024 22:06 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | Exercise / conversionShare Option (right to buy) · Derivative | 1,671 | $0.00 Strike: $5.84 | $0.00 |
DisclosureSEC source: 0001847903-24-000171 · wk-form4_1732313158.xml · derivative · entry 8 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,957,280 Underlying: Ordinary Shares · 1,671 shares Expires 2031-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: 25% of the shares subject to such option shall vest and become exercisable on February 19, 2022 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| November 22, 2024 Filed Nov 22, 2024 22:06 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | SaleOrdinary Shares | 1,671 | $18.24 | $30,478.37 |
DisclosureSEC source: 0001847903-24-000171 · wk-form4_1732313158.xml · nonDerivative · entry 5 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 575,661 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2024. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.23 to $18.305, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 22, 2024 Filed Nov 22, 2024 22:06 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | Exercise / conversionOrdinary Shares | 1,671 | $5.84 | $9,758.64 |
DisclosureSEC source: 0001847903-24-000171 · wk-form4_1732313158.xml · nonDerivative · entry 4 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 577,332 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| November 21, 2024 Filed Nov 22, 2024 22:06 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | Exercise / conversionShare Option (right to buy) · Derivative | 3,511 | $0.00 Strike: $5.84 | $0.00 |
DisclosureSEC source: 0001847903-24-000171 · wk-form4_1732313158.xml · derivative · entry 7 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,958,951 Underlying: Ordinary Shares · 3,511 shares Expires 2031-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: 25% of the shares subject to such option shall vest and become exercisable on February 19, 2022 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| November 21, 2024 Filed Nov 22, 2024 22:06 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | SaleOrdinary Shares | 3,511 | $18.24 | $64,028.35 |
DisclosureSEC source: 0001847903-24-000171 · wk-form4_1732313158.xml · nonDerivative · entry 3 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 575,661 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.23 to $18.255, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 21, 2024 Filed Nov 22, 2024 22:06 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | Exercise / conversionOrdinary Shares | 3,511 | $5.84 | $20,504.24 |
DisclosureSEC source: 0001847903-24-000171 · wk-form4_1732313158.xml · nonDerivative · entry 2 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 579,172 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| November 20, 2024 Filed Nov 22, 2024 22:06 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | SaleOrdinary Shares | 55,000 | $16.89 | $928,719.00 |
DisclosureSEC source: 0001847903-24-000171 · wk-form4_1732313158.xml · nonDerivative · entry 1 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 575,661 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.48 to $17.315, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 21:30 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | Exercise / conversionShare Option (right to buy) · Derivative | 32,023 | $0.00 Strike: $5.84 | $0.00 |
DisclosureSEC source: 0001847903-24-000169 · wk-form4_1731706240.xml · derivative · entry 4 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,962,462 Underlying: Ordinary Shares · 32,023 shares Expires 2031-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the shares subject to such option shall vest and become exercisable on February 19, 2022 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 21:30 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | SaleOrdinary Shares | 32,023 | $18.28 | $585,418.87 |
DisclosureSEC source: 0001847903-24-000169 · wk-form4_1731706240.xml · nonDerivative · entry 2 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 630,661 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.23 to $18.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 21:30 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | Exercise / conversionOrdinary Shares | 32,023 | $5.84 | $187,014.32 |
DisclosureSEC source: 0001847903-24-000169 · wk-form4_1731706240.xml · nonDerivative · entry 1 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 662,684 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| October 23, 2024 Filed Oct 23, 2024 21:27 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | SaleOrdinary Shares | 2,592 | $15.32 | $39,696.74 |
DisclosureSEC source: 0001847903-24-000160 · wk-form4_1729718836.xml · nonDerivative · entry 3 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 630,661 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2024. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.09 to $15.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 22, 2024 Filed Oct 23, 2024 21:27 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | SaleOrdinary Shares | 30,203 | $15.67 | $473,169.26 |
DisclosureSEC source: 0001847903-24-000160 · wk-form4_1729718836.xml · nonDerivative · entry 2 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 633,253 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.27 to $16.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 21, 2024 Filed Oct 23, 2024 21:27 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | SaleOrdinary Shares | 22,205 | $15.80 | $350,861.21 |
DisclosureSEC source: 0001847903-24-000160 · wk-form4_1729718836.xml · nonDerivative · entry 1 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 663,456 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.625 to $16.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 20:31 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | Tax withholdingOrdinary Shares | 36,263 | $15.79 | $572,592.77 |
DisclosureSEC source: 0001847903-24-000154 · wk-form4_1727901077.xml · nonDerivative · entry 1 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 685,661 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · shares: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted share units. Read SEC document |
| September 20, 2024 Filed Sep 20, 2024 20:55 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | SaleOrdinary Shares | 55,000 | $16.53 | $908,985.00 |
DisclosureSEC source: 0001847903-24-000145 · wk-form4_1726865706.xml · nonDerivative · entry 1 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 721,924 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.28 to $16.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 10, 2024 Filed Sep 13, 2024 00:01 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | Exercise / conversionShare Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $5.84 | $0.00 |
DisclosureSEC source: 0001847903-24-000142 · wk-form4_1726185660.xml · derivative · entry 4 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,994,485 Underlying: Ordinary Shares · 175,000 shares Expires 2031-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the shares subject to such option shall vest and become exercisable on February 19, 2022 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| September 10, 2024 Filed Sep 13, 2024 00:01 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | SaleOrdinary Shares | 175,000 | $16.52 | $2,891,822.50 |
DisclosureSEC source: 0001847903-24-000142 · wk-form4_1726185660.xml · nonDerivative · entry 2 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 776,924 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.23 to $17.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 10, 2024 Filed Sep 13, 2024 00:01 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | Exercise / conversionOrdinary Shares | 175,000 | $5.84 | $1,022,000.00 |
DisclosureSEC source: 0001847903-24-000142 · wk-form4_1726185660.xml · nonDerivative · entry 1 SAHA SAURABH · CIK 0001861926 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 951,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| August 30, 2024 Filed Sep 4, 2024 20:51 UTC | CLARIVATE PLC CLVT · Entity 4778 | SaleOrdinary Shares | 17,646 | $6.75 | $119,110.50 |
DisclosureSEC source: 0001764046-24-000122 · wk-form4_1725481722.xml · nonDerivative · entry 1 SAHA SAURABH · CIK 0001861926 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,741 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.